Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Calcimimetics].

P Messa1, G Como, B Brezzi

  • 1Divisione di Nefrologia, Dialisi e Trapianto, Ospedale Maggiore-Policlinico, Mangiagalli e Regina Elena, Fondazione IRCCS, Milan, Italy. pmessa@policlinico.mi.it

Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia
|March 8, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing the impact of structured reporting on learning how to report lung cancer staging CT: A triple cohort study on inexperienced readers.

European journal of radiology·2024
Same author

HBV infection is a risk factor for chronic kidney disease: Systematic review and meta-analysis.

Revista clinica espanola·2021
Same author

Vitamin D and subclinical cardiac damage in a cohort of kidney transplanted patients: a retrospective observational study.

Scientific reports·2020
Same author

Structured report for chest high-resolution computed tomography in patients with connective tissue disease: Impact on the report quality as perceived by referring clinicians.

European journal of radiology·2020
Same author

HBV infection is a risk factor for chronic kidney disease: Systematic review and meta-analysis.

Revista clinica espanola·2020
Same author

Long-term evaluation of coronary artery calcifications in kidney transplanted patients: a follow up of 5 years.

Scientific reports·2019

Calcimimetics effectively lower parathyroid hormone (PTH) and mineral levels in secondary hyperparathyroidism patients. These compounds offer a promising therapeutic advancement, though long-term monitoring is essential for patient safety.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Current therapies for secondary hyperparathyroidism in uremia show limited success in meeting NKF-K/DOQI guidelines for parathyroid hormone (PTH), calcium, and phosphate levels.
  • The calcium-sensing receptor (CaSR) plays a crucial role in regulating calcium and PTH secretion and is a target for novel therapeutic agents.
  • CaSR is expressed in various tissues, including parathyroid cells, and its modulation affects intracellular signaling pathways influencing hormone secretion and cell proliferation.

Purpose of the Study:

  • To evaluate the efficacy and safety of calcimimetics, particularly type II compounds like AMG 073, in managing secondary hyperparathyroidism in uremic patients.
  • To assess the impact of calcimimetics on parathyroid hormone (PTH), calcium, and phosphate levels, as well as the calcium x phosphate product.
  • To explore the potential of calcimimetics as an advancement in treating secondary hyperparathyroidism compared to existing therapies.

Related Experiment Videos

Main Methods:

  • Review of preclinical studies demonstrating calcimimetic effectiveness in reducing PTH, preventing hyperparathyroidism progression, and suppressing parathyroid cell proliferation.
  • Analysis of clinical studies, primarily focusing on AMG 073, in patients with primary and secondary hyperparathyroidism.
  • Evaluation of pharmacokinetic profiles, safety data, and adverse events associated with calcimimetic use, including hypocalcemia and gastrointestinal symptoms.

Main Results:

  • AMG 073 demonstrated efficacy in reducing PTH levels by over 30% in approximately 50% of uremic patients with secondary hyperparathyroidism.
  • Calcimimetic treatment resulted in a 5-7% reduction in calcium and phosphate serum levels, leading to a significant 15% decrease in the calcium x phosphate product.
  • Calcimimetics exhibited a favorable safety profile, with transient hypocalcemia and mild gastrointestinal discomfort being the main adverse events.

Conclusions:

  • Calcimimetics, especially AMG 073, represent a significant therapeutic advancement for secondary hyperparathyroidism in uremia, offering unique benefits in mineral metabolism control.
  • The observed reduction in the calcium x phosphate product is a notable pharmacological advantage over other treatments for secondary hyperparparathyroidism.
  • While effective, calcimimetic therapy requires strict clinical monitoring due to potential long-term consequences and the need for careful management of adverse events.